Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theralink Technologies Inc
THER
Healthcare
Biotechnology
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted...
treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:THER)
New Post
View:
Posts & Comments
Threaded Posts
(2)
•••
bolander
X
Post by
bolander
on Feb 12, 2018 12:57pm
LETTER OF INTENT
initiating trial of ProscaVax Feb/2018
(0)
•••
gobig1
X
Post by
gobig1
on May 09, 2017 11:44am
Corporate Update
Pretty lengthy, but an interesting read: https://www.marketwatch.com/story/oncbiomune-provides-corporate-update-nearly-50-drug-candidates-in-pipeline-or-being-negotiated-2017-05-09-111602855
Critical Mineral Executive Order Issued by President Donald Trump
posted Mar 25, 2025 9:00am by
Graphite One Inc.
-
|
"This new Critical Minerals Executive Order serves as the strongest signal yet that the U.S. Government has not only recognized the national security need for critical minerals including graphite, but that there will now be a 'whole of government' engagement to accelerate domestic development," said Anthony Huston, CEO of G1. ...read more
(6)
•••
zootv1
X
Post by
zootv1
on Mar 30, 2017 11:55am
News link.
https://www.google.ca/amp/www.marketwatch.com/amp/story/guid/189b9484-33f3-4e26-9cb5-abc073d6e3bf
(6)
•••
zootv1
X
Post by
zootv1
on Mar 30, 2017 11:54am
News...
j
(6)
•••
zootv1
X
Post by
zootv1
on Mar 27, 2017 10:55am
Big news . Sales Exceed forcast by 164%.
https://m.marketwired.com/press-release/oncbiomune-sales-bekunisr-cirkusedr-exceed-forecast-164-percent-first-six-months-on-otcqb-obmp-2205428.htm
(6)
•••
zootv1
X
Post by
zootv1
on Feb 02, 2017 11:20am
OncBioMune Announces Cancer Vaccine Poster Presentation
https://us12.campaign-archive2.com/?u=6bd487a01f6c6deed74d5ab46&id=eee7a06618&e=d1dbe1943a
(6)
•••
zootv1
X
Post by
zootv1
on Jan 27, 2017 7:07pm
Latest clinical data news release Jan 26th
https://m.canadianinsider.com/latest-clinical-data-from-oncbiomune-supports-safety-and-therapeutic-profile-of-proscavax-for-prostate-cancer-for-upcoming-phase-2-clinical-trials
(6)
•••
zootv1
X
Post by
zootv1
on Jan 20, 2017 6:40pm
OBMP may be EXTREMELY UNDERVALUED
OBMP may be extremely undervalued given the potential for a sub-$100M takeout of its intellectual property assets as the company moves toward further establishing those assets on the $7.1B stage of
...more
(6)
•••
zootv1
X
Post by
zootv1
on Jan 20, 2017 6:25pm
Could be the talk of Wall street
https://www.journaltranscript.com/2016/03/broke-out-inc-otcmktsbrko-inflates-further-could-oncbiomune-pharmaceuticals-otcqbobmp-be-next/
(6)
•••
zootv1
X
Post by
zootv1
on Jan 20, 2017 6:14pm
Departments of Urology and Oncology Approve Protocol for Onc
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico BATON ROUGE, LA -- (Marketwired) -- 01/18/17 -- OncBioMune
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Expanding opportunity: The re-refined Group III market represents less than 1% of the industry
Crypto Insights at Your Fingertips – View Now!
Critical Mineral Executive Order Issued by President Donald Trump
GBC AG Investment Research Analyst Report Indicates Strong Growth Forecast for DynaCert
The Value Play: Invest in One of the Largest Gaming Media Networks in North America